NEUmiRNA
Developer of ribonucleic acid therapies intended to treat neurological disorders. The company provides anti-miRNA treatment for transformative disease modification for neurological conditions, enablin...
Valuation
$0
Share Price
N/A
Total Raised
$22.1M
Last Round
N/A